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1. INTRODUCTION 
 
The growing number of genomic sequence, the description of genetic information 
from different species provides useful data to understand non-coding genes region 
evolutionary importance. When a mutation in the human genetic background is looked by 
researchers, they focus on the genes and their neighbouring control elements. The results of 
recent year supported, that the non-coding regions of genes have important role in the 
development of several diseases, they can causes gen tic abnormalities, they may predispose 
to disorders or on the contrary, they can be protectiv  agent too.  
 
1.1. The genetic background of IL23R gene  
 
Interleukins (IL) take part in development and activation of many cell. These 
molecules play a crucial role in the maturation anddifferentiation of cells. The name refers to 
the establishment of interactions between leukocytes.  
The interleukin-23 (IL23) which belongs to the IL12 familiy is primarily intracellular 
connection mediator glycoproteins with low molecular weight, which play important role 
during immune response in the transmission and regulation of the information. It was 
identified in 2000; it has a heterodimer structure, where its subunits are linked trough 
disulfide connections. IL23 is composed of the p19 domain, which is typical only for IL23; 
and of p40 domain, which is also a part of interleukin-12 (IL12).  
The IL23R tasks are very diverse. In chronic inflammation, antigen-stimulated 
dendritic cells and macrophages produce the IL23, which affects naive CD4+ T cells and 
promotes the development of Th17/ThIL-17 cells. These cells produce IL17, which enhances T 
cell priming and triggers potent inflammatory responses by inducing the production of a 
variety of inflammatory mediators.  
Cells expressing the receptor complex built from IL23R and IL-12Rβ1 are able to 
respond to IL23. The human IL23R gene locates on the short arm of chromosome 1 (1p31.3). 
The basic form of IL23R is coded by 11 exons; however through alternate splicing at least six 
different isoforms can be generated (IL-23R1-6). The most common deletions are deletion of 
exon 7 and/or 10. These variations result early termination of the protein leading to different 
forms of the extracellular domain, or to frameshift o  the open reading frame, resulting 
different length of intracellular domains. 
In a genome-wide association study Duerr et al found strong association between 
Crohn’s disease and IL23R polymorphisms, furthermore between IL23R gene and 
polymorphism of the neighboring intergenic region of the IL-12Rß1 gene. The authors 
published ten different single nucleotide polymorphisms (SNP), which represented strong 
significant association with this type of inflammatory bowel disease. Five polymorphisms, the 
rs10889677 in the 3’-untranslated region (3’-UTR), the intronic rs1004819 and rs2201841, 
furthermore the intergenic rs11209032 and rs1495965 were found as susceptibility factors in 
the development of the disease. However some others were found to be protective against CD: 
Arg381Gln (rs11209026) in the cytoplasmic domain, the intronic rs7517847, rs10489629, 
rs11465804 and rs1343151 mutations. 
Not much later, relationship between several autoimmune diseases and the examinded 
IL23R polymorphisms were found. The most studied diseases: psoriasis (PS), Sjögren’s 
syndrome (SS), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE).  
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1.2. The genetic background of IL28B és IL10R genes  
 
IL-28B belongs to the interleukin 10 familiy. It isexpressed by peripheral blood 
mononuclear cells, dendritic cells, and hepatocytes upon infection with viruses or stimulation 
with double-stranded RNA. IL28B in turn activates signal transduction through the JAK-
STAT pathway, exerts antiviral activity and has an impact on natural clearance of HCV. 
IL28B exhibits fewer IFN-like adverse effects because IL28B receptors are expressed on a 
limited number of cell types. The receptor for IL28 is composed of a unique IL-28R-α chain 
that pairs with the IL-10R-β chain.  
IL28B gene on human chromosome 19q (19q13.13) was discovered using genomic 
screening process in which the entire human genome was scanned for putative functional 
variants. It consists of 5 exons. 
Ge et al. identified first a SNP (rs12979860) located only 3 kilobases upstream from 
the IL28B gene, that encodes IL-28B. They applied gnome-wide association study (GWAS), 
retrospectively analysed samples of 1,137 HCV infected individuals participating in a clinical 
trial with pegylated interferon plus ribavirin (P/R) therapy, and found that the high IL-28B 
production CC genotype was associated with approximately a threefold greater rate of SVR to 
P/R when compared with the TT genotype. This finding was confirmed by others. At the same 
time it was also shown that the frequency of the CC genotype was significantly lower in HCV 
patients when compared to matched controls; thus, suggesting that this variant may be linked 
to a higher rate of natural clearance of HCV. This ypothesis was soon strengthened by 
Thomas et al., who reported that the IL28B CC genotype enhanced the spontaneous resolution 
rate of HCV infection. Thus, it became evident that HCV patients who harbor the CC 
genotype at rs12979860 are more prone to respond to P/R treatment and to clear the virus than 
patients who do not possess this genetic polymorphism. 
Interleukin-10 (IL10), whic belongs to the interleukin 10 family is produced by 
monocytes, macrophages and T cells, inhibits both the activation of CD4+ T-helper cells and 
the function of cytotoxic CD8 + T, NK and antigen-presenting cells, and also modulates 
hepatic stellate cell collagen synthesis. IL-10 plays  regulatory role in immune reaction and 
suppresses inflammatory responses by inhibiting the production of pro-inflammatory 
cytokines. Its effect is mediated through the IL-10 receptor (IL-10R), which is a heterodimer 
that consists of both IL-10R1 required for binding, and IL-10R2 required for signaling.  
The human IL10R gene is located on chromosome 11 (11q23), and it consists of 7 
exons. 
Increased IL-10 production was reported in associati n with the -1082G, -819C, -
592GCC IL-10 promoter (ATA) haplotype. If macrophages secrete large amount of IL-10, it 
may decrease circulating TFN-α and IL-6 levels, thus, reducing their harmful effects. A 
higher frequency of IL10 -1082 GG genotype was found in older healthy controls than in 
patients with myocardiac infarction; high IL-10 production was protective for longevity. 
 
1.3. The genetic background of PRDM1-ATG5 genes 
 
The human PRDM1 (positive regulatory domain I protein) also called BLIMP1 (B 
lymphocyte-induced maturation protein 1) gene is a a protein, which functionate as a 
repressor transcription factor. It play an important role in the regulation of different cellular 
processes such as cell proliferation, differentiation and apoptosis. It participates the final 
specialization of lymphocytes, epidermal cells, stem cells and other cell types, and it can be 
associated with the pathogenesis of human lymphoma. 
The transcript of the PRDM1 gene results two dissimilar mRNA types forming two 
different isoforms: the PRDM1 alpha and beta which share different types of cells. The 
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PRDM1 alpha is larger and more often expressed isoform, it contains 825 amino acids with a 
molecular mass of 92 kDa. The N-terminal part of the protein contains PR domain, while the 
C terminal region comprises five C2H2 type zinc finger, which provides the DNA binding 
domain. In the middle of this we can find the proline/serine-rich region. In contrast of this, the 
PRDM1 beta is shorter on the N-terminal side with 101 amino acid, thereby the PR domain is 
truncated. The PRDM1 beta transcriptional repressor functional activity is reduced.  
The PRDM1 expressed in many different tissues and organs, such as the 
hematopoietic system (plasma cells, B and T lymphocytes, NK cells, monocytes, granulocytes 
and dendritic cells), skin, central nervous system, testis, and intestine. In B cell population the 
expression will begin when it commits themselves to the final differentiation. It expressed in 
normal lymphoid cells, multiple myeloma and different lymphomas, which are under 
regulation of several transcriptional activator and repressor. Pasqualucci and his collegaues 
established that BLIMP1 operates as a tumor supressor gene, which inactivation leads to 
lymphoma’s developing. The two examined SNPs (rs4946728 and rs1040411) are located 
between the PRDM1 and the ATG5 (autofágia-related 5) genes in non-coding region.  
The ATG5 gene is one of the genes, which plays an essential function in the 
autophagosome late endosome and lysosome formation. The human ATG5 gene is located on 
the long arm of the 6. chromosome (6q21), it consists of eight exons (www.ensembl.org). Az 
The conjugation of ATG5-ATG12-vel is a key regulator of the autophagy process of natural 
anti-viral immune response. 
 
1.4. The genetic background of FCER2 gene 
 
The human FCER2 gene is located on chromosome 19 in position 19p13.3. This gene 
is responsible for the  encoding FcεRII /CD23 (low-affinity Immunoglobulin E receptor) 
integral membrane glycoprotein. The protein product of FCER2 gene is a 45 kDa protein 
which consists of 321 amino acids. 
The FcεRII receptor mediates various cellular biological processes; such as protection 
from apoptosis, the release of cytotoxic mediators and cellular adhesion. The principal role of 
the receptor is the synthesis of IgE down-regulation (through B lymphocytes), further it is 
responsible for the antigen presentation, maturation of T and B lymphocytes Proteolytic 
cleavage results FCER2 soluble form, which makes it unable to bind to the cell surface, and 
thereby terminate the negative feedback inhibition mechanism, resulting in increasing IgE 
levels. Presumably, this process will form the basis of various allergic reactions. 
The rs28364072 (T2206C) polymorphism in FCER2 gene is associated with elevated 
IgE level, severe asthmatic exacerbations and decreased gene expression. This polymorphism 
may play a role in the ineffective drug treatment because decreased therapeutic response was 
experienced using inhaled corticosteroids in patients carrying 2206C variant of FCER2 gene. 
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1.5. Autoimmune disorders 
 
Ankylosins spondylitis (AS) 
 
The ankylosing spondilitis also known Bechtrew-disease is a chronic, inflammatory 
and progressive disease of the spinal and sacroiliac joints, especially characterized with 
calcification of the joints and ligaments. As a consequence of these results a rigid spine. The 
peripheral joins are affected in the one third of the cases. It can develop in 20 to 30 years, both 
sexes are afftected; however it is more common in ma , than women. As the joint surfaces die 
due to the inflammation, the joins calcificates, the vertebrae begin to grow together, and 
beaklike lumps are formed on their edges. SPA may affect the entire body. It can develop 
extraintestinal manifestation, the most common is the uveitis anterior, that causes continuous 
inflammation of the eyes, sensitivity to light, increased tear production is also specific for the 
disease. 
 
Systemic lupus erythematosus (SLE) 
 
The SLE is an autoimmune disorder with chronin inflammation, the symptoms can 
affect the whole body system. In the background of the disease are several factors, genetic, 
immunolological, environmental and hormonal. Known risk factors of ultraviolet radiation, 
smoking and a number of environmental toxins. In males and females occur both but in 
women of child-bearing period most often, when the hormon system changes. General 
symptoms include fever, fatigue, joint pain, loss of appetite and weight loss. The skeletal 
system, skin and respiratory system is primarily affected. The redness may occur in the face, 
which form a characteristic feature in lupus "butterfly" rash. Manifestations are furthermore: 
sores around the mouth and nose, the Raynaud syndrome and alopecia. Muscosceletal 
symptoms are arthritis in the muscles, and pain in the joints. Respiratory symptoms are cough, 
shortness of breath. When the cardiovascular system is affected pericarditis, miocarditis, 
endocarditis, when the nervous system is affected, h adaches, depression, anxiety, stroke, 
when the excretory organ system is affected glomerulonephritis can occur. 
 
Sjögren’s syndrome (SS) 
 
Sjögren's syndrome or Sjögren syndrome is a chronic autoimmune disease in which 
the body's white blood cells destroy the exocrine glands, specifically the salivary and lacrimal 
glands, that produce saliva and tears, respectively. The immune-mediated attack on the 
salivary and lacrimal glands leads to the development of xerostomia and keratoconjunctivitis 
sicca, which takes place in association with lymphocytic infiltration of the glands. That 
inflammatory process eventually severely damages or destroys the glands. Common 
symptoms of burning, itching and foreign body sensation in the eye, dysgeusia, tongue edge 
cracking. The SS is an multifactorial disease affecting origin, such as environmental, 
hormonal and genetic factors in a cross. Genetic predisposition study revealed that in 
individuals with genetic predisposition a viral or ther infections can be the cause of the 
disease.  
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Psoriasis (PS) 
 
Psoriasis is a genetically determined, polygenic inheritance skin disease, associated 
with increased proliferation of keratinocytes, paracer tosis, dermal inflammation, vascular 
and immunological abnormalities and T cell proliferation in the skin. Recent research 
emphasize the role of IL17 and IL23 cytokines. The inhibition of these treatment options 
come in through. The disease has polygenic inheritance, but enviromental factors are also 
important in the development of the disease, stress, triggering climatic conditions may be 
included as a factor in subjects with a predisposition o the disease. In the beginning, just at 
certain predilection areas show wax-white, stout and flaky deposits covered papules, this can 
remind us to dried candle wax. In other cases, especially in pediatric cases, millet size, in the 
later phase scaly, small and bright red papules occur on the whole body (psoriasis eruptiva, 
psoriasis guttata). Predilection sites of the sympto s are the surfaces areas exposed to 
irritation: elbows, knees, scalp, areas under the breasts, genitofemoral bend, perianal area and 
the external genitalias.  The PS can develop in any ages, but there are stages of life, when the 
disease is more common (in 15 to 20 and in 55 to 66). 
 
Inflammatory bowel disease (IBD)  
 
The pathogenesis of IBD is very complex and both enviro mental and genetic factors 
contribute to its etiology. Environmental factors may be infectious agents, drugs, poisons, 
smoking, alcohol, and bowel bacteria as well. The genetic background has a particular 
importance, people may have genetic susceptibility and show reduced resistance of the 
mucosa or abnormal activation of the immune system in the intestines. These together with 
environmental factors cause inflammation. IBD may develop in a susceptible individual when 
the normal hostmicrobial interactions are dysregulated. The normal host-microbial flora 
consists of 300-400 different strains of bacteria. This balance can overturn, when people have 
chronic inflammatory bowel disease. This time the concentration of certain bacteria, such as 
Bacteroides increases causing inflammation. External bacteria can be also responsible for 
IBD.  
There are two main types of inflammatory bowel disease (IBD), Crohn's disease (CD) 
and ulcerative colitis (UC). 25-30.000 people in Hungary have IBD. The disease may occur in 
persons adults between ages 20 and 40 in both sex, although women are more frequently 
affected. There are many extraintestinal manifestations associated with inflammatory bowel 
disease, for instance eye and mouth inflammation, skin rash, gallstones, kidney stones, 
pancreatitis and joint pain. 
Crohn’s disease is a chronic inflammation of uncertain etiology that can affect any 
portion of the digestive tract from mouth to anus. Inflammation occurs primarily in the ileum 
and colon, although any portion of the intestinal tr ct can be affected. Ileocolitis is the most 
common form affecting the ileum and the colon. Ileitis only affects the ileum, while 
granulomatous colitis only affects the colon. The intestinal inflammation can appear in the 
terminal ileum (terminal ileitis) or might occur insome parts of the ileum (regional enteritis) 
or the colon (Crohn-colitis). Symptoms include abdominal pain, diarrhea, bloody stools, 
fistulas, fever, loss of appetite, vomiting, weight loss, growth retardation, indisposition and 
late of puberty. 
Ulcerative colitis is a disease that causes inflammtion and ulcers in the lining of the 
rectum and colon. When the inflammation occurs in the rectum it is called proctitis. If the 
entire colon is affected it is called pancolitis. Proctosigmoiditis involves inflammation of the 
rectum and the sigmoid colon, while left–sided colitis involves inflammation that starts at the 
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rectum and extends up the left colon (sigmoid colon and the descending colon). Symptoms 
range from abdominal pain, cramps, bloody diarrhea, t nesmus, fever, anemia, loss of body 
fluids and nutrients, to decreased level of protein and iron. 
 
Rheumatoid arthritis (RA) 
 
It is a disease with unknown etiology, affecting the joins with chronic inflammatory, 
where genetic factors may contribute to the development of the disease. Bacterial or viral 
infection is presumed (Myobacterium, Proteus, Streptococcus, Chlamydia species, parvovirus 
B19, rubella, HIV viruses).  
In systemic, autoimmune diseases, the body treats theirs own connective tissue 
elements as foreign, defending against them with inflammatory reaction. During this process, 
the intima of the joint thickens due to the inflammation and synovial fluid builds up. All these 
prevent the normal function, preventing the movement of the joint. Muscle spasms occur and 
at a later stage the angled form of the joint will be stabilized. During inflammation different 
lesions occur: degradation of the joints and surrounding areas, tendonitis is very common, 
rheumatoid nodules may appear in the skin, and different bone deformations may also 
develop. After disease manifestation, painful joint distorsion of the connective tissue or bony 
joint stiffness develops in the later stage.  
Based on epidemiological data, RA is a very common disease, it affects 0.5-0.5% of 
the population, in Hungary approx. 100,000 people. Over 16 years of age, it can develop at 
any age, but most often in 40 to 50 years of age. Practically, it occurs everywhere on the 
world, but the incidence, the course and the severity of the disease may be different among 
ethnic groups. 
 
1.6. Hepatitic C virus infection (HCV) 
 
Hepatitis C virus (HCV) is a major global health problem: currently 170 million 
subjects are suffering from HCV infection worldwide, incubation period is from 2 to 25 week. 
The outcome of HCV infection ranges from spontaneous viral clearance to hepatitis, cirrhosis 
and hepatocellular carcinoma. Some individuals have r pidly progressive liver disease, while 
others remain symptom-free virus carriers. The exact c uses of the different disease courses 
are not known. Immune mechanisms, as well as enviromental factors are responsible for the 
various HCV-related events.  
In case HCV infection outcome the main determinant is host's immune response, 
beside the specificity of virus and certain enviromental factors. The elimination of HCV is 
natural (innate) immune response, on the other hand the adaptive function, polyclonal CD4 
and CD8 T-cell responses. In this process the major agent are the major histocompatibility 
complex (MHC) molecules and the cytokines produced by immun cells (this is under control 
by genetic factors). 
Previously, mainly viral hepatitis in human leukocyte antigens (HLA) and disease 
association correlations tested, however, the coding gene variants of cytokines are also 
studied. Genome-wide association study (GWAS)) method and the SNPs analysis are became 
suitable to examine genetic variants in the neighbour region of IL28B gene and promoter 
region of IL10R gene. 
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1.7. Hodgkin’s lymphoma (secondary malignancy)  
 
Hodgkin's lymphoma, also called Hodgkin's disease mainly affecting the lymph nodes, 
it is a  lymphocyte-derived malignant disease (called. ymphoma), which was given the name 
of Thomas Hodgkin, who first described the characteristics of the disease. 
Hodgkin's disease usually begins in one lymph node group, often in the head and neck, 
less frequently in the armpit or in the groin area. This disease has specific, predictable pattern. 
It spreads from lymph node to the neighboring lymph nodes in the body. Extranodal 
involvement occurs only in the advanced stage of the disease (eg. marrow, liver). The general 
symptoms are: fever, weight loss, night sweats, itching all over the body. Characteristics may 
be also decreasing the performance, and after the consumption of alcohol pain can be detected 
in lymph nodes. The dysfunction of T-lymphocytes may result that the patients are  
susceptible to TBC, fungal and viral infections can develop. Furthermore, there may be 
neurological disorders, hormonal disorders, bone, lung involvement and urogenital 
complaints. 
Determining the outcome is very important the stage of the disease and the presence of 
the risk factors. The good prognosis in turn reduces th  radiation therapy and late toxicity of 
chemotherapy. Here we can mention the increased risk of secondary tumors (particularly 
breast and thyroid cancer) 15 years after the radiation (11%), appearance of acute myeloid 
leukemia in the first 10 years (1%) and development of on-Hodgkin's lymphoma. 
A recent GWAS study identified two non-coding SNPs (rs4946728 and rs1040411) 
between the PRDM1 and the ATG5 regions, which are risk factor for secondary malignancy 
after radiation therapy in childhood Hodgkin's lymphoma patients. 
 
  
1.8. Asthma 
 
Bronchial asthma is a complex etiology, chronic, multifactorial inflammatory disease 
which affects the respiratory system. The prevalence of the disease is high, more than 300 
million people are affected worldwide. Typical symptoms are wheezing, cough, shortness of 
breath.  
The disease usually starts (70-80% of the cases) in child or young adulthood as a result 
of ordinary, everyday allergens such as pollen, dust, animal dander, foods or drugs. 
Epidemiological studies have revealed that in addition o genetic factors, a number of other 
risk factors may affect disease progression, such as ethnicity, gender, diet, occupation, breast-
feeding, viral- and microbial infections, domestic animals, exposure to tobacco smoke. 
With using the genetic informations the primary goal f the pharmacogenetic research 
are to tailor the drug therapy to individual with maximize the impact and minimizing the toxic 
side effects. In recent years asthma pharmacogenetic studies great emphasis has been placed 
among other things to study the low-affinity IgE receptor gene (FCER2) polymorphisms, 
which may be responsible for the symptoms in patients with asthma aggravation. 
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1.9. Description and the main characteristics of Roma population 
 
The Roma population size is estimated to be about 12–15 million in the world. From 
this, 10–12 million people lives in Europe. The largest number (70%) of European Roma 
population is concentrated in Central and South-Eastern Europe. Hungary is the fourth in 
Europe considering the estimated size of the Romas, with about 550-600.000 people. In Roma 
population the general morbidity rate is elevated, the infant mortality is fourfold increased, 
they have specific private disease-associated mutations, and their life expectancy is less with 
ten years compared to Central and Eastern European populations. 
As the Roma people have clear genetic diversity compared with the surrounding 
nations with their relatively highly conserved gene pool deriving ultimately from India, 
similar to other pharmacogeneticaly relevant polymorphisms we supposed differences 
between the Hungarian and Roma population examining several non-coding genetic 
polymorphisms. 
 
2. AIMS 
 
The aim of our experiments was to highlight the importance of non-coding region 
polymorphisms of several genes. 
 
Our aim was to analyze four susceptibility IL23R genetic variants: the rs10889677, which is 
located in the 3’UTR region of the gene and three intronic variants, rs1004819 and 
rs2201841, the intergenic rs11209032. We also studied one protective polymorphisms of the 
IL23R gene too, the intronic rs7517847. We wanted to examine, if there are significant 
genetic differences between Hungarian and Roma group, that can be susceptibility or 
protective indicator factor in the given population. 
 
A further aim was to examine the rs4946728 and rs1040411 noncoding SNPs located between 
PRDM1 and ATG1 genes on chromosome 6q21 as risk factors for secondary malignancies in 
patients formerly treated with radiotherapy for pediatric Hodgkin disease. Our aim was to 
draw conclusions which of the two ethnic groups aremore vulnerable to secondary 
malignancy.  
 
Our aim was also to investigate the non-coding rs28364072 SNP of the FCER2 gene in Roma 
and Hungarian population, which is responsible for the symptoms exacerbation of asthma and 
determine genetic difference between the two group.  
 
Another goal was to analyze the rs12979860 SNP of the IL28B and the rs1800896 SNP of the 
IL10R gene, and ascertain if these variants have influence on HCV patients comparing the 
results with healthy controls. 
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3. PATIENTS AND METHODS 
 
3.1. Study populations 
 
For the genotype analysis of IL23R gene (rs10889677, rs1004819, rs2201841, 
rs11209032 and rs7517847) we used 273 DNA samples from Romas (103 man, 170 female) 
and 253 healthy control DNA (104 male, 149 female).  
A total of 748 HCV1 infected patients (365 men, 383 female, ranging in age from 18 to 
82 years, mean 54 ± 10 years) were enrolled. Of the 748 HCV1 patients, 420 were treated with 
pegylated interferon alfa 2a/2b (Pegasys, Hoffmann-La Roche Inc./Pegintron, SP Labo N.V. 
Belgium) 135–180 µg/1.0-1.5 µg/kg subcutaneously per week, and ribavirin (Copegus, 
Hoffmann-La Roche Inc./Rebetol, SP Labo N.V. Belgium) 1000–1200 mg orally per day for 
24–72 weeks, then followed up for 24 weeks. Subjects who had undetectable HCV RNA 
levels following 24 weeks of therapy were designated as sustained virological response (SVR), 
undetectable serum HCV RNA at week 4 after starting treatment as rapid virological response 
(RVR), undetectable HCV RNA at week 12 after starting therapy as early virological response 
(EVR). In our paper, patients who did not achieve SVR were regarded as “non-responders” 
(non-SVR). One hundred and five healthy individuals (64 men, 41 female, mean age 45 ± 3 
years), who were consecutive voluntary blood donors with normal liver function tests and 
negative for HBV, HCV and HIV serology, served as controls.  
For rs4946728 and rs1040411 SNPs localized between the PRDM1 and the ATG5 
gene region DNA samples from a total of 289 Hungarians (166 males and 123 females, mean 
age: 37 ± 1.00, range: 18-64 yrs) and 293 Roma subjects (124 males and 169 females, mean 
age: 55 ± 1.02, range: 13-90 yrs) were tested. 
In addition, discovery, replication and combined cases and control groups taken from 
the study of Best et al at Nature Medicine 2011 were enrolled to our analyses.4 The discovery 
set consisted of 96 SMN cases (19 males, 77 females) nd 82 SMN-free controls (31 males, 
51 females). All cases and controls were individuals of European descent diagnosed with 
Hodgkin’s lymphoma as children (median age: 15.6, range: 8–20) and treated with 25–44 Gy 
radiation therapy with or without alkylating chemotherapy. Cases developed SMNs with a 
mean latency of 20.0 years (s.d. = 5.8 years, range: 6–34). Controls were followed for at least 
27 years (median: 32 years, range: 27–38) to ensure that the maximal contamination of 
controls by future cases was < 2%. To replicate their findings, an independent set of 62 cases 
with SMNs (6 males, 56 females) and 71 SMN-free controls (14 males, 57 females) were 
enrolled, all treated for Hodgkin’s lymphoma in child ood with 25–44 Gy mediastinal 
radiation therapy. The replication cases and controls were self-identified as white, non-
Hispanic. The genotypes and allele frequencies of the PRDM1 variants were also analyzed in 
combined set of discovery and replication collection of patients. 
For the rs28364072 SNP of the FCER2 gene 458 Roma (206 male, 252 female) and  
397 Hungarian (222 male, 175 female) DNA samples were used. 
 
3.2. Molecular biological methods 
  
The molecular analyses were performed using DNA extracted from peripheral 
blood leukocytes with a routine salting out procedure. PCR–RFLP methods were applied 
to test the alleles of the IL23 receptor gene, using the following forward and reve se 
primers: for rs10889677 forward primer: 5’-ATC GTG AAT GAG GAG TTG CC-3’ and 
reverse primer: 5’-TGT GCC TGT ATG TGT GAC CA-3’; for rs1004819 forward primer: 5’- 
GCA TTC TAG GAC CGT TTT GG-3’ and reverse primer:  5’-ATC TGG TGG AAA TAT 
GTG AAA CCT A-3’; for rs2201841 forward primer: 5’-GGC AAA AGG GAA TTG AGA 
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GG-3’ and reverse primer: 5’-GGC CTA TGA TTA TGC TT TTC CTG-3’; for rs11909032 
forward primer: 5’-TTG TTA CTG GAG TTA AAC CTC TTG C-3’ and reverse primer: 5’-
AGG AAT AAT TGC TGA GAT GCA ATG-3’; for rs7517847 forward primer: 5’-AAA 
CAT TGA CAT TCC CTT CAT AC-3’ and reverse primer: 5’-GAA ATG AGT CAC CAA 
TAA TCC AC-3’. The following restriction endonucleases were used for the digestion, MnlI 
for rs10889677, TaaI for rs1004819, HpyF3I for rs2201841, BseMI for rs11209032 , BseMII 
for the rs7517847 SNP. 
The IL28B rs12979860 SNP was determined using Custom Taqman SNP Genotyping 
Assays (Applied Biosystems, Life Technologies, Foster, CA, USA). The IL10R −1087 (also 
known as IL10R −1082) (rs1800896) promoter region was required for the formation of the
EcoNI recognition sequence 5′-AAGACAACACTACTAAGGCT-3′; the lower primer was 
5′-TAAATATCCTCAAAGTTCC-3′. EcoNI restriction enzyme was used for digestion.  
The PRDM1-ATG5 gene regions SNPs, rs4946728 and rs1040411 were determined 
two predesigned TaqMan SNP Genotyping Assays (Applied Biosystems, Life Technologies, 
Foster, CA, USA). 
The FCER2 rs28364072 SNP was also determined using Custom Taqman SNP 
Genotyping Assays (Applied Biosystems, Life Technologies, Foster, CA, USA) with 
specified conditions. 
 
3.3. Statistical analysis 
 
 To the evaluation of the relationship between the dis ases, the genetic variants and the 
haplotypes, χ2-test and regression analysis was used. Analyses were carried out SPSS 20.0 
package for Windows.  
 
4. RESULTS 
 
4.1. IL23R gene 
 
All IL23R genotype and allele frequencies were in Hardy–Weinberg equilibrium both 
in Hungarian and in Roma subjects. The rs10889677 AA (24.5% vs. 5.93%, p < 0.05), 
rs1004819 AA (24.2% vs. 9.49%, p < 0.05), rs2201841 CC (20.5% vs. 6.32%, p < 0.05) and 
rs11209032 AA (19.0% vs. 9.49%, p < 0.05) homozygous genotype frequencies were 
significantly increased in the Roma group compared to the Hungarian samples. The 
rs10889677A (48.5% vs. 29.8%, p < 0.05), rs1004819A (47.9% vs. 30.2%, p < 0.05), 
rs2201841C (46.1% vs. 28.9%, p < 0.05) and rs11209032A (43.2% vs. 33.2%, p < 0.05) allele 
frequencies were also significantly over-represented in the Roma population compared to the 
healthy Hungarian controls. The rs7517847 showed significantly decreased GG homozygous 
genotype frequency in Roma samples (5.13%), while it was 16.2% in the Hungarian subjects 
(p < 0.05). The frequency of allelic variants and genotypes of IL23R in the Roma group and 
Hungarian controls are shown in Table 1. 
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Table 1.: Genotypes and minor allele frequencies of IL23R polym rphisms. 
  
   Roma (273) Hungarian (253)      
  IL23R genotype          
  IL23R rs10889677          
  CC 75 (27.5%) 117 (46.2%)      
  CA 131 (48.0%) 121 (47.8%)      
  AA 67 (24.5%)* 15 (5.93%)      
  A allele frequency 48.5%* 29.8%      
  IL23R rs1004819          
  GG 77 (28.2%) 124 (49.0%)      
  GA 130 (47.6%) 105 (41.5%)      
  AA 66 (24.2%)* 24 (9.49%)      
  A allele frequency 47.9%* 30.2%      
  IL23R rs2201841          
  TT 77 (28.2%) 123 (48.6%)      
  TC 140 (51.3%) 114 (45.1%)      
  CC 56 (20.5%)* 16 (6.32%)      
  C allele frequency 46.1%* 28.9%      
  IL23R rs11209032          
  GG 89 (32.6%) 109 (43.1%)      
  GA 132 (48.4%) 120 (47.4%)      
  AA 52 (19.0%)* 24 (9.49%)      
  A allele frequency 43.2%* 33.2%      
  IL23R rs7517847          
  TT 129 (47.3%) 74 (29.2%)      
  TG 130 (47.6%) 138 (54.5%)      
  GG 14 (5.13%)* 41 (16.2%)      
  G allele frequency 28.9%* 43.5%      
  
 
 
* p<0.05 vs. Hungarian 
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4.2. IL28B and IL10R genes 
When comparing the IL28B genotype frequencies between groups of healthy controls 
and patients, the CC genotype occurred with lower fr quency in HCV patients than in 
controls, thus, suggesting its protective effect against chronic hepatitits C. On the other hand, 
CT heterozygosity and T alleles were more prevalent in patients, and may, therefore, convey 
susceptibility for the disease (Table 2.). Subjects that received P/R therapy and who had the 
IL28B CC genotype achieved higher rates of SVR than subjects who had CT genotype (58.6% 
vs 40.8%) (OR 2.057, 95% CI: 1.305-3.058, p = 0.002), or those carrying the T allele (41.8%, 
OR 1.976, 95% CI: 1.263-3.058, p = 0.002) (Table 3.). 
IL10R GG genotype occurred with lower frequency in patients (31.8%) than in 
controls (52.2%) (OR: 0.428, p < 0.001). The prevalence of IL10R AA allele was 68.15% in 
patients and 47.8% in healthy individuals (OR: 2.335, p < 0.001). Among P/R treated patients 
with SVR, the IL10R GG genotype occurred with higher fr quency than the AA genotype, 
(57/178, 32.0% vs 31/178, 17.4%, (OR: 1.84, 95% CI 1.13-2.98, p = 0.013). The SVR rate in 
patients with IL10R GG genotype was 42.2% (59/125); in those with GA 47.4% (88/178) and 
in AA patients 39.7% (31/78). HCV patients with A allele (non-GG genotype) achieved SVR 
in 46.4% (119/256) (Table 4.). 
Table 2.: Prevalence of IL28B genotypes in Hungarian HCV patients and healthy controls. 
 
  HCV1 
(n=748) 
Controls 
(n=105) 
IL28B genotype    
rs12979860 CC 195 (26.1%)* 54 (51.4%) 
CT 411 (54.9%)* 39 (37.1%) 
TT 142 (19.0%) 12 (11.4%) 
T allele frequency 553 (73.9%)* 51 (48.6%) 
 
 
 
Table 3.: Sustained virological response (SVR) rate stratified by IL28B genotypes in 
Hungarian HCV patients. 
 
  Treated    SVR  
IL28B genotype n Number of patients % 
CC 116 68 58,6 
CT 228 93 40,8 
TT 76 34 44,7 
T allele (non-CC) 304 127 41,8 
 
ILB28 CC vs. CT     OR: 2.057 (1.305–3.236), p = 0.002* 
IL28B CC vs. TT     OR: 1.751 (0.975–3.134), p = 0.059 
IL28B CC vs. T (non-CC)                         OR: 1.976 (1.263–3.058), p = 0.002 
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Table 4.: Prevalence of IL10R −1087 genotypes in HCV patients a d healthy controls. 
 
  HCV1 
(n=672) 
Controls 
(n=92) 
IL10R genotype    
rs1800896 GG 214 (31.8%) 48 (52.2%) 
GA 333 (49.6%) 32 (34.8%) 
AA 125 (18.6%) 12 (13.0%) 
A allele frequency 458 (68.15%) 44 ( 7.8%) 
 
 
 
4.3. PRDM1-ATG5 gene region 
 
The profile of allelic variants for both of rs4946728 and rs1040411 SNPs of the 
PRDM1-ATG5 gene region, including the risk-associated minor allele frequencies did not 
significantly differ between the Hungarian and Roma samples. The Roma and the Hungarian 
samples predisposing variants frequencies did not differ statistically from the same variants of 
the replication, discovery and combined conrols (Best et al.). 
The homozygous carriers of the PRDM1 rs4946728 risk C allele were much frequent 
in the Hungarian and Roma subgroups compared to the discovery and combined controls 
presented by Best et al. In the Roma subgroup, the het rozygous carriers of the PRDM1 
rs4946728 risk C allele were significantly prevalent compared to all three control groups. In 
addition, considerable accumulation of the PRDM1 rs4946728 risk C allele was observed in 
both the Hungarian and Roma populations compared to the discovery and combined controls 
(79.4 and 83.5% vs. 59.1 and 63.7%; p<0.05). 
The homozygous carriers of the PRDM1 rs1040411 risk A allele were significantly 
frequent in the Hungarian and Roma subgroups compared to the discovery and combined 
controls. Statistically significant accumulation of the PRDM1 rs1040411 risk A allele was 
detected in the Hungarian and Roma populations compared to the discovery controls (56.4 
and 56.8% vs. 39.6%; p<0.05). Besides, in the Hungarian subgroup, the frequency of the 
rs1040411 risk A allele was higher than in combined controls, as well (56.4% vs. 44.1%; 
p<0.05).  
The risk alleles of PRDM1 variants (rs4946728 C; rs1040411 A) did not show 
accumulation in neither the Hungarian nor the Roma groups compared to the discovery, 
replication and combined cases. The allele frequencies observed among the “Cases” groups 
by Best et al. did not also significantly differ from those of our sample groups for either 
PRDM1 variant. 
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Table 5.: Distribution of the PRDM1 rs4946728 genotypes in Hungarian and Roma 
population samples, with cases and controls from Best et al. 
 
rs4946728 
Group 
Genotype Risk allele frequency 
(%) 
A/A (n) A/C (n) C/C (n) 
Roma 7abc 78abc 194ac 83.5ac 
Hungarian 7abc 100 170ac 79.4ac 
Discovery Casesf 2 23 71 86.0 
Replication Casesf 1 17 43 84.4 
Combined Casesf 3 40 114 85.3 
Discovery Controlsf 12 43 27 59.1 
Replication 
Controlsf 
6 32 33 69.1 
Combined Controlsf 18 75 60 63.7 
 
a p<0.05 vs. „discovery” Controls 
b p<0.05 vs. „replication” Controls 
c p<0.05 vs. „combined” Controls 
d p<0.05 vs. „discovery” Cases 
e p<0.05 vs. „combined” Cases 
f Calculated from genotype count data of table 1 of Timothy Best et al. (Best és mtsai 2011). 
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Table 6.: Distribution of the PRDM1 rs1040411 genotypes in Hungarian and Roma 
population samples, with cases and controls from Best et al. 
 
rs1040411 
Group 
Genotype Risk allele frequency 
(%) 
A/A (n) A/G (n) G/G (n) 
Roma 84ac 140 52acde 55.8a 
Hungarian 84ac 141 49acd 56.4ac 
Discovery Casesf 42 47 7 68.2 
Replication Casesf 22 30 9 60.6 
Combined Casesf 64 77 16 65.3 
Discovery Controlsf 10 45 27 39.6 
Replication Controlsf 18 33 19 49.3 
Combined Controls f 28 78 46 44.1 
 
a p<0.05 vs. „discovery” Controls 
b p<0.05 vs. „replication” Controls 
c p<0.05 vs. „combined” Controls 
d p<0.05 vs. „discovery” Cases 
e p<0.05 vs. „combined” Cases 
f Calculated from genotype count data of table 1 of Timothy Best et al. (Best és mtsai 2011). 
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4.4. FCER2 gene 
 
Examining the intronic FCER2 T2206C polymorphism, we found significant differenc s for 
CC homozygous genotype (p=0.032) compared the Roma population with Hungarian 
controls. The homozygous presence of the minor 2206C allele in Roma participants is more 
than twofold decreased than in Hungarians (2.8% vs 5.8%). The predisposing C allele 
frequency was similar in the two populations (24.8% vs 24.6%). 
 
Table 7.: Genotypes and minor allele frequencies of FCER2 polym rphism in Roma and 
Hungarian populations. 
 
  
Roma 
(n=458) 
Hungarian 
(n=397) 
FCER2 genotypes    
rs28364072 TT 244 (53.3%) 225 (56.7%) 
TC 201 (43.9%) 149 (37.5%) 
CC 13 (2.8%)* 23 (5.8%) 
C allele frequency 24.8% 24.6% 
 
* p<0.05 vs. Hungarian 
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5. DISCUSSION OF THE RESULTS AND CONCLUSIONS 
 
After the recognition of the importance of DNA, the researchers focused on the coding 
region of DNA, but 98% their part is non-coding sequ nce. It revealed that these “junk DNAs 
have an important significance, the larger part of the human genome is non-coding 
(pseudogene, gene fragments, non-translated region), several are outside of the gene or 
between the genes (extragenic sequence).  
The 80% of the extrageneic sequences is unique or low copy numbers, smaller part is 
strongly iterative. These can be tandem repeats and dispersed repetitive sequences. 
The tandem repeats are short DNA sequences that occur only in certain chromosome 
segments. Is subdivided into three classes: satellite DNA, minisatellite DNA, microsatellite 
DNA.  
Tandem repeats phases influence the activity of the neighboring genes. The repetitions 
determined how closely the DNA twists into a special shape called nucleosomes, and that the 
tunneling mechanism that determines the extent to which genes can be activated. 
 Level of genes very important are the introns and the non-translated regions. The 
largest part of DNA are the introns, based on these that introns have diverse biological 
functions, regulatory and structural targets. The 5’UTR region is necessary to linkage to 
mRNA ribosome, thereby these are key player in the normal protein synthesis. When a 
mutation occurs in this region, that can change the w ole process or certain parts. 
 In case of gene mutation not only the extent of the mutation (the length of the DNA 
sequence) is important, but also the location. No matter whether there are mutations in the 
coding or non-coding region or even the border of the two. These is splicing mutation exon-
intron boundary sequences play an important role in several process. As a result of a splicing 
mutation an exon can lost or an intron can translate, these can result in defective protein. 
It can be said that the non-coding regions have an important role, their mutations can 
be the cause of development of several diseases. In the dissertation 10 SNP were investigated, 
the rs10889677 of IL23R located in the 3’UTR region; six intronic polymorphisms 
(rs1004819, rs2201841, rs7517847 of the IL23R, rs12979860 of the IL28B, rs1800896 of the 
IL10R, rs28364072 of the FCER2) and three intergenic variant (rs11209032 between th  
IL23R and the IL12Rß1 region, rs4946728, rs1040411 between the PRDM1 and the ATG5 
region). Our aim was to examine these variants in Roma nad Hungarian population (we 
studied HCV patients and controls in case of IL28B and IL10R), and draw conclusion, which 
population is more susceptible to the studied disease.  
Examining the IL23R variants, the A allele and AA homozygous genotype frequencies 
of rs10889677,  rs1004819, and rs11209032 SNPs and the C allele and homozygous CC 
genotype frequencies of rs2201841SNP were significatly increased in Roma group, so 
carrying these SNPs means higher risk to develop autoimmune diseases. Evaluate the results 
of rs7517847 SNP of the IL23R gene the G allele andthe GG homozygous genotype 
frequencies were significantly decreased in the Roma group comparing the result to the 
healthy controls, so carrying this variant is probably a protective factor against develop 
autoimmune diseases. 
Examining IL28B rs rs12979860 SNP the C allele and CC homozygous genotype 
frequencies were significantly decreased in the HCV patients’s group, so carrying this variant 
is a protective factor against HCV infection. The rs1800896 of IL10R gene showed 
significantly decreased G allele and GG homozygous genotype frequencies, so carrying this 
variant protect against HCV disease.  
We investigated the rs4946728 and the rs1040411 noncodi g SNPs located between 
the PRDM1 and the ATG1 genes on chromosome 6q21, which are risk factors for secondary 
malignancies in patients formerly treated with radiotherapy for pediatric Hodgkin disease and  
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we could not detect significant difference between the allele and the genotype frequencies 
compare the Roma group to Hungarians. So it can concluded that the groups are exposed the 
same to secondary malignancy after radiation therapy. 
The pharmacogeneticcally important FCER2 rs28364072 CC homozygous genotype 
freqeuncy was significantly decreased in Roma population compare the results to Hungarians. 
So we can expect decreased expression of the receptor protein in Hungarian population that 
causes the icreased IgE level which can be responsible for the exacerbation of inflammatory 
symptoms. Results of these the conventional drug therapy can be reduced in the Hungarian 
population than in the Roma group.  
The non-coding region are very important, they have sp cial significance for certain 
diseases susceptibility, as well as pharmacogenetic point of view. The variants can cause 
individual differences in drug metabolism and thereby influence the therapeutic response. 
There are differences between nations, the common message of the the dissertation is this.  
 
6. SUMMARY OF THE RESULTS 
 
1. Our aim was to investigate autoimmune diseases associ ted IL23R gene variants 
(rs10889677, rs1004819, rs2201841, rs7517847 és rs11209032 SNPs) examining 273 Roma 
and 253 healthy Hungarian controls. IL23R rs10889677, rs1004819, rs2201841 és rs11209032 
SNPs showed increased minor allele and homozygous genotype frequencies in the Roma 
group, so carrying these varaints means susceptibility factor for autoimmune diseases in 
Romas. IL23R rs7517847 SNP showed decreased G allele and homozygous GG genotype 
frequencies in the Roma cohort, so carrying this variant is probably a protective factor against 
develop autoimmune diseases. 
 
2. During the examination of rs12979860 SNP of IL28B  we analyzed 748 HCV patients 
and 105 controls, while in case of IL10R rs1800896 SNP 672 HCV patients and 92 controls 
were the subjects of the investigation.  IL28B rs12979860 SNP showed decreased C allele and 
CC homozygous genotype frequencies in HCV group, so carrying this variant means a 
protective agent against HCV infection. The  rs1800896 SNP os IL10R gene the G allele and 
the GG homozygous genotype showed decreased frequencies, so carrying this variant is a 
protective factor against HCV infection. 
 
3. Examining the rs4946728 and the rs1040411 noncoding SNPs located between the 
PRDM1 and the ATG1 genes on chromosome 6q21, which are risk factors for secondary 
malignancies in patients formerly treated with radiotherapy for pediatric Hodgkin disease on 
293 Roma and 289 Hungarian DNA samples we could not detect significant difference 
between the allele and the genotype frequencies compare the two groups. So it can concluded 
that the groups are exposed the same to secondary malignancy after radiation therapy. 
 
4. Investigating the pharmacogeneticcally important FCER2 rs28364072 SNP (which is 
responsible for the symptoms exacerbation of asthma) on 458 Roma and 397 Hungarian DNA 
samples, we could detect that the CC risk homozygous genotype frequency is lower in the 
Roma group. In Hungarian population the increased CC risk homozygous genotype freqeuncy 
may predict higher asthmatic disease incidence. 
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